Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-021-04732-4
Abstract: Significant advances in supportive care for patients with transfusion-dependent thalassemia major (TDT) have improved patients’ life expectancy. However, transfusion-associated iron overload remains a significant barrier to long-term survival with good quality of life. Today, allogeneic… read more here.
Keywords: treosulfan fludarabine; fludarabine based; fludarabine; busulfan fludarabine ... See more keywords
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Sign Up to like & getrecommendations! Published in 2019 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2019.09.002
Abstract: OBJECTIVE/BACKGROUND Busulfan/cyclophosphamide (Bu/Cy) and busulfan/fludarabine (Bu/Flu) are both standard myeloablative conditioning (MAC) regimens for allogeneic hematopoietic cell transplantation (alloHCT). We compared the effectiveness of these regimens with a focus on quality of life (QOL). METHODS… read more here.
Keywords: busulfan; cell; busulfan fludarabine; allogeneic hematopoietic ... See more keywords